Cargando…
AAV9 transduction mediated by systemic delivery of vector via retro-orbital injection in newborn, neonatal and juvenile mice
Adeno-associated virus (AAV)-based gene therapy is gaining popularity owing to its excellent safety profile and effective therapeutic outcomes in a number of diseases. Intravenous (IV) injection of AAV into the tail vein, facial vein and retro-orbital (RO) venous sinus have all been useful strategie...
Autores principales: | Prabhakar, Shilpa, Lule, Sevda, da Hora, Cintia Carla, Breakefield, Xandra O., Cheah, Pike See |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Association for Laboratory Animal Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614020/ https://www.ncbi.nlm.nih.gov/pubmed/34039790 http://dx.doi.org/10.1538/expanim.20-0186 |
Ejemplares similares
-
Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1
por: Prabhakar, Shilpa, et al.
Publicado: (2019) -
Targeting the somatosensory system with AAV9 and AAV2retro viral vectors
por: Skorput, Alexander G. J., et al.
Publicado: (2022) -
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2
por: Prabhakar, Shilpa, et al.
Publicado: (2022) -
Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin
por: Cheah, Pike-See, et al.
Publicado: (2021) -
Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors
por: Wang, Qizhao, et al.
Publicado: (2016)